-- First clinical trial with lead candidate HTL0022562 (BHV3100) to be conducted by Sosei Heptares
-- Candidate discovered by Sosei Heptares and developed successfully through preclinical development demonstrating promising and differentiated properties to target CGRP-mediated disorders
-- Tenth GPCR-targeted drug candidate overall generated from Sosei Heptares' structure-based drug design (SBDD) platform to enter clinical development
PR Newswire
TOKYO and CAMBRIDGE, England, June 23, 2021